Physician profile
Stephen Martiny
NPI 1528212602
$4,803.09
in general payments reported to CMS, 2019-2025
25 companies · $555 in 2025
The $555 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $827 · 2020: $625 · 2021: $595 · 2022: $537 · 2023: $970 · 2024: $695 · 2025: $555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,103 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,103.14 |
| Education | $116.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $858.59 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $697.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $456.14 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $445.50 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $275.37 | 2019-2024 | Jardiance |
| Pfizer INC. | $254.31 | 2022-2025 | |
| Amarin Pharma, INC. | $238.74 | 2019-2020 | |
| Amgen INC. | $216.75 | 2019-2025 | Repatha, Otezla, Otezla |
| Kowa Pharmaceuticals America, INC. | $183.21 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $173.35 | 2019-2024 | Trintellix |
| Merck Sharp & Dohme LLC | $162.32 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Glaxosmithkline, LLC. | $132.89 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbott Laboratories | $122.26 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Eisai INC. | $105.68 | 2020-2025 | |
| Esperion Therapeutics, INC. | $90.37 | 2022-2025 | Nexletol |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $80.39 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $75.32 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $53.27 | 2019-2020 | |
| Inspire Medical Systems, INC. | $47.38 | 2025 | Inspire |
| Biohaven Pharmaceuticals, INC. | $37.42 | 2021 | |
| Allergan, INC. | $23.67 | 2020 | |
| Lundbeck LLC | $21.27 | 2023 | Vyepti |
| Bayer Healthcare Pharmaceuticals INC. | $20.32 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.72 | 2022 | |
| Upsher-Smith Laboratories LLC | $11.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Martiny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.